Meeting
2019 ASCO Annual Meeting
Association of sex, age and ECOG performance status with cancer immunotherapy efficacy in randomized controlled trials.
Authors
Fang Yang
The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University & Clinical Cancer Institute of Nanjing University, Nanjing, China
Fang Yang , Yucai Wang , Grzegorz S. Nowakowski , Michael Wang , Ashish V. Chintakuntlawar , Thorvardur Ragnar Halfdanarson , Lance C. Pagliaro , Jia Wei , Baorui Liu , Julian R. Molina , Svetomir Markovic
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Health Services Research, Clinical Informatics, and Quality of Care
Track
Quality Care/Health Services Research
Sub Track
Outcomes
Citation
J Clin Oncol 37, 2019 (suppl; abstr 6592)
DOI
10.1200/JCO.2019.37.15_suppl.6592
Abstract #
6592
Poster Bd #
283
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Identification of RPTOR mutation as a novel predictor of efficacious immunotherapy in melanoma.
First Author: Yongzhao Li
Poster
2022 ASCO Annual Meeting
Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study.
First Author: Lyndsey L Prather
Poster
2021 ASCO Annual Meeting
Improving patient and caregiver understanding of risks and benefits of immunotherapy for melanoma or lung cancer.
First Author: Laura A Petrillo
Poster
2020 ASCO Virtual Scientific Program
Gut microbiome to predict efficacy and immune-related toxicities in patients with advanced non-small cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy.
First Author: Taiki Hakozaki